A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics

Koethe, John R.; Westfall, Andrew O.; Luhanga, Dora K.; Clark, Gina M.; Goldman, Jason D.; Mulenga, Priscilla L.; Cantrell, Ronald A.; Chi, Benjamin H.; Zulu, Isaac; Saag, Michael S.; Stringer, Jeffrey S. A.
March 2010
PLoS Clinical Trials;Mar2010, Vol. 7 Issue 3, Special section p1
Academic Journal
Background:The benefit of routine HIV-1 viral load (VL) monitoring of patients on antiretroviral therapy (ART) in resource-constrained settings is uncertain because of the high costs associated with the test and the limited treatment options. We designed a cluster randomized controlled trial to compare the use of routine VL testing at ART-initiation and at 3, 6, 12, and 18 months, versus our local standard of care (which uses immunological and clinical criteria to diagnose treatment failure, with discretionary VL testing when the two do not agree). Methodology: Dedicated study personnel were integrated into public-sector ART clinics. We collected participant information in a dedicated research database. Twelve ART clinics in Lusaka, Zambia constituted the units of randomization. Study clinics were stratified into pairs according to matching criteria (historical mortality rate, size, and duration of operation) to limit the effect of clustering, and independently randomized to the intervention and control arms. The study was powered to detect a 36% reduction in mortality at 18 months. Principal Findings:From December 2006 to May 2008, we completed enrollment of 1973 participants. Measured baseline characteristics did not differ significantly between the study arms. Enrollment was staggered by clinic pair and truncated at two matched sites. Conclusions:A large clinical trial of routing VL monitoring was successfully implemented in a dynamic and rapidly growing national ART program. Close collaboration with local health authorities and adequate reserve staff were critical to success. Randomized controlled trials such as this will likely prove valuable in determining long-term outcomes in resource-constrained settings


Related Articles

  • Preventive misconception and adolescents' knowledge about HIV vaccine trials. Ott, Mary A; Alexander, Andreia B; Lally, Michelle; Steever, John B; Zimet, Gregory D // Journal of Medical Ethics;Dec2013, Vol. 39 Issue 12, p765 

    Objective Adolescents have had very limited access to research on biomedical prevention interventions despite high rates of HIV acquisition. One concern is that adolescents are a vulnerable population, and trials carry a possibility of harm, requiring investigators to take additional...

  • Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV. Roland, Michelle E.; Neilands, Torsten B.; Krone, Melissa R.; Katz, Mitchell H.; Franses, Karena; Grant, Robert M.; Busch, Michael P.; Hecht, Frederick M.; Shacklett, Barbara L.; Kahn, James O.; Bamberger, Joshua D.; Coates, Thomas J.; Chesney, Margaret A.; Martin, Jeffrey N. // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1507 

    Background. The efficacy of antiretroviral postexposure prophylaxis (PEP) against infection with human immunodeficiency virus (HIV) following occupational exposures has prompted the use of PEP after nonoccupational exposures. There are, however, important differences between occupational and...

  • HIV Antiretroviral Postexposure Prophylaxis: A Cautionary Note. Cohen, Myron S.; Kashuba, Angela D. M.; Gay, Cynthia // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1514 

    Presents the authors' opinions on the role of antiretroviral therapy in preventing the sexual transmission of human immunodeficiency virus (HIV) infection. Discussion on clinical trials to evaluate the efficacy of antiretroviral therapy; Views on the benefits of pre-exposure prophylaxis;...

  • Once-Daily versus Twice-Daily Lopinavir/Ritonavir in Antiretroviral-Naive HIV-Positive Patients: A 48-Week Randomized Clinical Trial. Eron, Joseph J.; Feinberg, Judith; Kessler, Harold A.; Horowitz, Harold W.; Witt, Mallory D.; Carpio, Felix F.; Wheeler, David A.; Ruane, Peter; Mildvan, Donna; Yangco, Bienvenido G.; Bertz, Richard; Bernstein, Barry; King, Martin S.; Sun, Eugene // Journal of Infectious Diseases;1/15/2004, Vol. 189 Issue 2, p265 

    The safety, pharmacokinetics, and antiviral activity of lopinavir, a human immunodeficiency virus (HIV) protease inhibitor, coformulated with ritonavir as a pharmacokinetic enhancer were evaluated in 38 antiretroviral-naive patients randomized 1:1 to receive open-label lopinavir/ritonavir at a...

  • Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012). Boyd, Mark A.; Dixit, Narendra M.; Siangphoe, Umaporn; Buss, Neil E.; Salgo, Miklos P.; Lange, Joep M. A.; Phanuphak, Praphan; Cooper, David A.; Perelson, Alan S.; Ruxrungtham, Kiat // Journal of Infectious Diseases;11/1/2006, Vol. 194 Issue 9, p1319 

    The availability of enfuvirtide enables assessment of whether human immunodeficiency virus (HIV) decay can be enhanced by targeting reverse transcriptase, protease, and fusion. We performed a 12-week study of 22 patients randomized to receive ritonavir-boosted saquinavir and efavirenz with (the...

  • PrEParing the way. Murphy, Dean // HIV Australia;2011, Vol. 9 Issue 3, p9 

    The article presents results of several clinical trials of various antiretroviral (ARV)-based HIV prevention strategies. The HPTN 052 trial showed that initiation of ARV treatment by the partner who is HIV-positive revealed a 96% decrease in HIV transmission. A Phase III clinical trial named...

  • Translating Efficacy into Effectiveness in Antiretroviral Therapy. Fletcher, Courtney V. // Drugs;2007, Vol. 67 Issue 14, p1969 

    Durable and sustained suppression of HIV replication can be achieved as demonstrated in several recent clinical trials of antiretroviral (ARV) regimens. However, the efficacy demonstrated in the experimental setting does not always translate to effectiveness in the clinical setting. The...

  • Raltegravir. Croxtall, Jamie D.; Lyseng-Williamson, Katherine A.; Perry, Caroline M. // Drugs;2008, Vol. 68 Issue 1, p131 

    Raltegravir, the first in a new class of orally administered HIV type-1 (HIV-1) integrase inhibitors, selectively inhibits the strand transfer activity of HIV-1 and its integration into human DNA, a key stage in retroviral propagation, thereby limiting viral replication and the infection of new...

  • Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. Cauldbeck, Mary B.; O'Connor, Catherine; O'Connor, Mortimer B.; Saunders, Jean A.; Rao, Bhimasena; Mallesh, V. G.; Praveen Kumar, Nagendrappa Kotehalappa; Mamtha, Gurushanthappa; McGoldrick, Claire; Laing, Robert B. S.; Satish, Kadappa Shivappa // AIDS Research & Therapy;2009, Vol. 6, Special section p1 

    Introduction: Human Immunodeficiency Virus (HIV) has an estimated prevalence of 0.9% in India (5.2 million). Anti-retroviral drugs (ARV) are the treatments of choice and non-adherence is an important factor in treatment failure and development of resistance, as well as being a powerful predictor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics